Home
Search results “Seattle genetics antibody cures for cancer”
Meet Our Members: Seattle Genetics, Inc.
 
02:35
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. They are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity. Learn more: http://www.seattlegenetics.com/
Clay Siegall - My Fearless Idea Fights Cancer
 
01:00:05
Clay Siegall tells the story of Seattle Genetics, and the development of antibody-drug conjugates for cancer therapy. Recorded at Bioscience Day 2014 at the University of Maryland.
Views: 1316 UMD Science
Seattle Genetics
 
02:59
Seattle Genetics is passionate about making a positive impact on the lives of patients with cancer. Employees bring that enthusiasm to everything they do, striving to attain their individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. View this career recruitment video to learn about Seattle Genetics' culture and hear directly from chemists, clinical researchers and sales professionals. As a company working at -- and advancing -- the cutting edge of antibody-based therapies, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground and creates opportunities for intellectual and professional growth. State-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping. If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards for making your best even better. We want to hear from you!
Views: 354 MadDash
Seattle Genetics
 
03:19
Seattle Genetics is passionate about making a positive impact on the lives of patients with cancer and autoimmune diseases. Employees bring that enthusiasm to everything they do, striving to attain their individual goals while recognizing the power of working collaboratively to realize Seattle Genetics' vision of improving patient outcomes. View this career recruitment video to learn about Seattle Genetics' culture and hear directly from chemists, clinical researchers and sales professionals. As a company working at -- and advancing -- the cutting edge of antibody-based therapies, Seattle Genetics fosters an environment that recognizes the challenges of breaking new ground and creates opportunities for intellectual and professional growth. State-of-the art facility gives our team members the resources to succeed. Located in Bothell's Canyon Park area, Seattle Genetics is close to major highways, dining and shopping. If you are passionate about bringing the best of yourself to everything you do, Seattle Genetics offers challenges, opportunities and rewards for making your best even better. We want to hear from you!
Views: 1623 MadDash
Seattle Genetics' Siegall `Excited' by Cancer Drug Data: Video
 
04:39
Oct. 11 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., discusses the results from a clinical trial of its SGN-35 drug for treating anaplastic large cell lymphoma. The drug, also known as brentuximab vedotin, uses an antibody to home in on cancer cells. Siegall, speaking with Betty Liu and Adam Johnson on Bloomberg Television's "In the Loop," also discusses the prospects that his company may become a takeover target. (Source: Bloomberg)
Views: 437 Bloomberg
Seattle Genetics' Siegall Discusses Lymphoma Treatment: Video
 
02:34
June 8 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., talks with Bloomberg's Adam Johnson about clinical trial data for the company's brentuximab vedotin treatment for Hodgkin lymphoma. They speak at the Jefferies 2010 Global Life Sciences Conference in New York. (Source: Bloomberg)
Views: 289 Bloomberg
Gene Therapy Cure Cancer
 
01:07
This is my final project for science subject at my school. I learning about biotechnology. My topic is about " How gene therapy can cure cancer?" and i have to fin the solution. I am very sorry i copyrighted this video from a youtube video that i got it, i copy some of part your video. Your video very helping for me to get a better score i hope i can get a good score. Thankyou for that! Credits to owners: http://www.youtube.com/watch?v=5SC2EoxUOXo don't forget to like this video:)
Views: 66 della lathifah
Seattle Genetics CEO: Addressing Unmet Needs | Mad Money | CNBC
 
06:39
Seattle Genetics' has put cancer squarely in its sights. Will the pipeline powered by its breakthrough science propel the stock higher? Jim Cramer spoke to CEO Clay Siegall to find out. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Seattle Genetics here: http://cnb.cx/2g15k4K "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Read the latest news: http://madmoney.cnbc.com Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Visit CNBC.com: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Seattle Genetics CEO: Addressing Unmet Needs | Mad Money | CNBC
Views: 717 CNBC
Seattle Genetics Plunges After Issuing Stage 3 Trial Results
 
01:44
Investors are not reacting favorably to the Seattle Genetics' stage three trial results for its lymphoma treatment.
Dr. Fanale on Brentuximab Vedotin as Frontline Treatment for Lymphoma
 
01:33
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma (ALCL). For more ASH 2012 coverage: http://www.onclive.com/conference-coverage/ash-2012
Views: 168 Targeted Oncology
Adcetris
 
16:12
Hodgkin's Lymphoma cured with Adcetris.
Views: 616 Joe Lawyer
How is the landscape of Hodgkin lymphoma therapy changing?
 
02:48
Anas Younes, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses changes in the landscape of Hodgkin lymphoma therapy at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains that because of the high curability of Hodgkin lymphoma, research was not focused on developing new therapies. However, Prof. Younes speaks about two new drugs which have recently changed how Hodgkin lymphoma is treated, the antibody-drug conjugate brentuximab vedotin and immune checkpoint inhibitors, and discusses their mechanisms of action and how they can be combined. He also discusses which factors need to be considered for new therapies, including value and long-term safety.
Seattle Genetics CEO on Front-Line Therapy for Advanced Hodgkin Lymphoma
 
02:19
At the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, Rare Disease Report sat down with Clay Siegall, PhD, CEO of Seattle Genetics, who discussed the ADCETRIS and the evolving paradigm in treatment for patients with advanced Hodgkin lymphoma.
With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?
 
08:57
Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.
Seattle Genetics Prices 10 Mln Shares at $15.50 Each, Shares Off 2.5%
 
00:29
Seattle Genetics (SGEN) says it priced 10 million shares at $15.50 each in a public offering. It has granted the underwriters a 30-day option to purchase up to an aggregate of 1.5 million additional shares of common stock to cover overallotments, if any. The offering is expected to close on or about February 7.
Seattle Genetics Shares Fall Despite Positive Results from Hodgkin's Drug Study
 
00:41
"Shares of Seattle Genetics (SGEN) are off 5%, following positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. The results are better than expected, but the commercial potential of the drug may be limited because of ""the small market opportunity,"" Bloomberg reported, citing Canaccord Genuity analyst George Farmer. Seattle Genetics shares are down 5.23%, or $0.83, to $15.04."
Views: 179 FinancialNewsOnline
Seattle Genetics
 
02:01
VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global securities. About The Video: We believe that complex financial data could become more approachable using friendly motion-graphic representation combined with an accurate selection of financial data. To guarantee the most effective information prospective we drew inspiration from Benjamin Graham’s book: “The Intelligent Investor”, a pillar of financial philosophy. For this project any kind of suggestion or critic will be helpful in order to develop and provide the best service as we can. Please visit our site www.whyinvestin.com and leave a massage to us. Thank you and hope you'll enjoy. IMPORTANT INFORMATION - DISCLAIMER THIS VIDEO IS FOR INFORMATION PURPOSES ONLY AND SHOULD NOT BE RELIED UPON AS INVESTMENT ADVICE. This video has been prepared by Whyinvestin (together with its affiliates, “Whyinvestin”) and is not intended to be taken by, and should not be taken by, any individual recipient as investment advice, a recommendation to buy, hold or sell any security, or an offer to sell or a solicitation of offers to purchase any security. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. The performance of the companies discussed on this video is not necessarily indicative of the future performances. Investors should consider the content of this video in conjunction with investment reports, financial statements and other disclosures regarding the valuations and performance of the specific companies discussed herein. DO NOT RELY ON ANY OPINIONS, PREDICTIONS OR FORWARD-LOOKING STATEMENTS CONTAINED HEREIN. Certain of the information contained in this video constitutes “forward-looking statements” that are inherently unreliable and actual events or results may differ materially from those reflected or contemplated herein. None of Whyinvestin or any of its representatives makes any assurance as to the accuracy of those predictions or forward-looking statements. Whyinvestin expressly disclaims any obligation or undertaking to update or revise any such forward-looking statements. EXTERNAL SOURCES. Certain information contained herein has been obtained from third-party sources. Although Whyinvestin believes such sources to be reliable, we make no representation as to its accuracy or completeness. FINANCIAL DATA. Historical companies’ data, ratios, exchange rate, prices and estimates are provided by Factset research www.factset.com . Whyinvestin does not verify any data and disclaims any obligation to do so. Whyinvestin, its data or content providers, the financial exchanges and each of their affiliates and business partners (A) expressly disclaim the accuracy, adequacy, or completeness of any data and (B) shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. Neither Whyinvestin nor any of our information providers will be liable for any damages relating to your use of the information provided herein. Please consult your broker or financial representative to verify pricing before executing any trade. Whyinvestin cannot guarantee the accuracy of the exchange rates used in the videos. You should confirm current rates before making any transactions that could be affected by changes in the exchange rates. You agree not to copy, modify, reformat, download, store, reproduce, reprocess, transmit or redistribute any data or information found herein or use any such data or information in a commercial enterprise without obtaining prior written consent. Please consult your broker or financial representative to verify pricing before executing any trade. COPYRIGHT “FAIR USE” Whyinvestin doesn’t own any logo different from the whyinvestin’ s logo contained in the video. The owner of the logos is the subject of the video itself (the company); and all the logos are not authorized by, sponsored by, or associated with the trademark owner . Whyinvestin uses exclusive rights held by the copyright owner for Educational purposes and for commentary and criticism as part of a news report or published article. If you are a company, subject of the video and for any reason want to get in contact with Whyinvestin please email: company@whyinvestin.com
Views: 11 Why Invest In
An Answer to Cancer? Using the immune system to fight cancer -- Longwood Seminar
 
01:32:16
Oncologists are turning to a novel form of therapy to combat cancer: retraining or reengineering the immune system to quash tumor growth. In this seminar, hear from Harvard Medical School scientists and clinicians on the latest approaches that use the body’s own defenses to fight cancer. Speakers: - Arlene Sharpe, MD, PhD - Catherine J. Wu, MD - Jerome Ritz, MD - David F. McDermott, MD Like Harvard Medical School on Facebook: https://goo.gl/4dwXyZ Follow on Twitter: https://goo.gl/GbrmQM Follow on Instagram: https://goo.gl/s1w4up Follow on LinkedIn: https://goo.gl/04vRgY Website: https://hms.harvard.edu/
Dr. Diehl Discusses Brentuximab Vedotin
 
01:52
Volker Diehl, MD, Professor of Medicine, Emeritus, University of Cologne, Germany, discusses the recently approved drug brentuximab vedotin (SGN-35), an antibody-drug conjugate that has been approved to treat anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma. It is marketed as Adcetris by Seattle Genetics, Inc. Brentuximab vedotin builds on the CD30 tumor marker discovered 30 years ago in cell line L428. CD30 is present in ALCL and Hodgkin lymphoma. The naive monoclonal antibody anti-CD30 is ineffective by itself and requires the combination with another agent to be successful. Diehl describes the chemists at Seattle Genetics as being very intelligent for adding a "bump" to the antibody in the form of monomethyl auristatin E (MMAE), a microtubule inhibitor. Once MMAE enters the CD30-expressing tumor it prevents mitosis within the cells, which causes targeted cell death. The use of brentuximab vedotin in refractory and far advanced relapsing patients with Hodgkin's lymphoma resulted in an approximate complete remission of 35%. This drug is currently being used in combination with Adriamycin (doxorubicin), vinblastine, and dacarbazine (ABVD) in the US. In Germany a new regimen was constructed by modifying BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone) in order to incorporate brentuximab vedotin. The modifications leave out procarbazine and long-term prednisone while adding brentuximab vedotin, dacarbazine, and dexamethasone.
Views: 1376 OncLiveTV
New therapies for high risk Neuroblastoma
 
47:03
Professor Julie Park Seattle Children's Hospital
What are Antibody-drug Conjugates (ADCs)?
 
03:33
Antibody-drug conjugates or ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies (mAbs) with the potent cell killing activity of cytotoxic small molecule drugs. The key components of antibody-drug conjugates include a monoclonal antibody (mAbs), a stable linkers and a cytotoxic (anticancer) agents. Monoclonal antibodies are attached to biologically active drugs by chemical linkers with labile bonds. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. Antibody-drug conjugates are part of a specialized and technically challenging type of therapy combining innovations from biotechnology and chemistry to form a new class of highly potent biopharmaceutical drugs. For more information go to ADC Review / Journal of Antibody-drug Conjugates to read the full article: "What are Antibody-drug Conjugates (ADCs)?" (http://tinyurl.com/mzop4sj) This educational video was produced by Genentech, A Member of the Roche Group.
A New Frontline Treatment Option for Hodgekin Lymphoma
 
40:01
Source: https://www.spreaker.com/user/7078249/joseph-connors-interview_1 In this Edition of The Onco'Zine Brief Peter Hofland, Ph.D and Sonia Portillo talk with Joseph M. Connors, MD., FRCPC, Clinical Director, Center for Lymphoid Cancer (Retired 2018) and Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma. In this interview Dr. Connor talks about the some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) for patients with advanced classical Hodgkin Lymphoma. The phase III ECHELON-1 study, was designed to evaluate brentuximab vedotin as part of a front-line chemotherapy regimen for previously untreated advanced classic Hodgkin lymphoma. The trial met its primary endpoint of modified progression-free survival in 2017. The latest data from the study was presented during the 2017 American Society of Hematology Annual Meeting & Expostion and simultaneous publication in The New England Journal of Medicine. Now, brentuximab vedotin is an approved drug and commercially available in the United States. The ECHELON-1 trial was important for the approval by the FDA of a so called ‘fifth approval or line expansion’ of the drug.
Seattle Genetics - New Hire Orientation Video
 
02:28
www.kirklandvideoproduction.com Videography, Editing and Motion Graphics: Rich Rudy Gaffer, Grip, AD: Dahlin Call Synopsis: This is a new hire orientation video for Seattle Genetics. The video was shot on the Canon C100, edited in Premiere Pro, using Photoshop and After Effects for motion graphics. About Seattle Genetics: Seattle Genetics is the largest global oncology biotechnology company based in the Pacific Northwest. We are focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. For more information about Seattle Genetics, please visit their website at: www.seattlegenetics.com About Kirkland Video Production: Kirkland Video Production is a full service corporate video production company. We offer a wide range of videography services including; shooting, editing, script writing, motion graphics and much more. Whether you need end-to-end video production or you have small bits of the production process that you need to outsource, Kirkland Video Production can handle all your Corporate Videography needs. We've served clients and agencies of all sizes and has a wide range of corporate video experience including producing, writing, shooting and editing all of the following types of videos: TV commercials, marketing videos, non profit fundraiser videos, web videos, event highlight videos, product videos, training videos, TV Shows, and many other custom video projects. Tell use about your next video project! (206)218-7175 rich@kirklandvideoproduction.com
Healthy Outlook?
 
06:17
Seattle Genetics' has put cancer squarely in the sites of its targeted treatment technology. Will the pipeline powered by this breakthrough science propel its stock higher? Mad Money's Jim Cramer interviews the CEO.
Views: 531 CNBC
(SGEN) Seattle Genetics, Inc.
 
05:21
(SGEN) Seattle Genetics, Inc.
Views: 96 Bill Gunderson
V4P5: ADCs: Part of the Renaissance of Targeted Therapy and  Personalized Medicine Approaches
 
01:10
Watch as Tom Reynolds, Chief Medical Officer of Seattle Genetics, describes the renaissance of targeted therapy and personalized medicine approaches and where antibody drug conjugates fit into this spectrum.
Views: 44 GreenHillHC
Vol 4. Part 2: Targeting Therapy Utilizing Antibody Drug Conjugates
 
01:51
Watch as Tom Reynolds, Chief Medical Officer of Seattle Genetics, describes the targeted mechanism of action of antibody drug conjugates and their impact on personalized medicine in oncology.
Views: 429 GreenHillHC
Seattle Genetics Inc. Final Project Engineering Econ
 
09:24
Engineering econ Seattle genetics
Views: 52 BOB Thebuilder
V4P9: Relationship Between Biomarker Prevalence  and the Targeted Therapy
 
01:15
Tom Reynolds, Chief Medical Officer of Seattle Genetics, discusses how best to identify patients who will respond to antibody drug conjugate therapy in Part 9 of our Interview with the Innovators series.
Views: 40 GreenHillHC
In US, a shocking shortage of cancer drugs
 
02:18
Cancer patient Carey Fitzmaurice has battled cancer for six years. But now she can't get access to the chemotherapy drug recommended by her doctor. Cancer drug shortages are a growing problem in the United States, highlighting the dangerous shortcomings of the world's most expensive health care system.Duration: 02:17
Views: 1087 AFP news agency
Targeted Therapies: Monoclonal Antibodies
 
05:42
Video presentation on targeted therapies utilising monocolonal antibodies such as Herceptin and Adcertis.
Views: 26 Zak Hassan
News Update: Seattle Genetics Tumbles 4% After Leukemia Drug Trials Fail
 
00:53
Seattle Genetics (NASDAQ:SGEN) is trading 4% lower Monday after the company reported its leukemia drug known as lintuzumab, failed its trial, and that it has opted to discontinue development. Specifically, the key trial showed that the biotechnology treatment did not extend the lives of patients with acute myeloid leukemia. The drug was licensed by Seattle Genetics in 2005 when PDL BioPharma Inc (NASDAQ:PDLI) decided to not pursue the antibody following disappointing results from leukemia trials. SmarTrend currently has Seattle Genetics in a Downtrend and is currently monitoring these developments and will alert subscribers to any change of trend.
Views: 220 TradeTheTrend
Seattle Genetics | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks
 
02:14
http://tinyurl.com/biotechmillionaire ◄ CLICK HERE To Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks! Tags seattle genetics seattle genetics stock seattle genetics jobs seattle genetics news seattle genetics pipeline seattle genetics address seattle genetics glassdoor seattle genetics salary seattle genetics investor relations seattle genetics buyout seattle genetics inc seattle genetics adcetris seattle genetics aml seattle genetics adc seattle genetics ash 2016 seattle genetics annual report seattle genetics abbvie seattle genetics astellas seattle genetics and takeda seattle genetics alcanza seattle genetics bothell seattle genetics benefits seattle genetics business development seattle genetics board seattle genetics bothell washington seattle genetics bloomberg seattle genetics baker brothers seattle genetics breakthrough seattle genetics bayer seattle genetics careers seattle genetics clinical hold seattle genetics ceo seattle genetics cd33 seattle genetics clinical trials seattle genetics canada seattle genetics cfo seattle genetics cancer drug seattle genetics ceo scandal seattle genetics cd40 seattle genetics deaths seattle genetics drugs seattle genetics divorce seattle genetics daiichi sankyo seattle genetics dividend seattle genetics dennis benjamin seattle genetics drug approval seattle genetics darren cline seattle genetics dlbcl seattle genetics deal seattle genetics fellowship seattle genetics fda seattle genetics financials seattle genetics fellowship brochure seattle genetics founders seattle genetics finance seattle genetics facebook seattle genetics food truck seattle genetics forum seattle genetics fucose seattle genetics google finance seattle genetics grants seattle genetics genentech seattle genetics general counsel seattle genetics genmab seattle genetics gsk seattle genetics growth is seattle genetics a good investment seattle genetics headquarters seattle genetics hold seattle genetics h1b seattle genetics hiring seattle genetics history seattle genetics hodgkin's lymphoma seattle genetics homepage seattle genetics after hours seattle genetics company history seattle genetics stock history seattle genetics internships seattle genetics inc stock seattle genetics ipo seattle genetics interview questions seattle genetics in the news seattle genetics inc. linkedin seattle genetics inc. (sgen) seattle genetics intern seattle genetics jefferies seattle genetics jonathan drachman seattle genetics jim cramer seattle genetics jp morgan seattle genetics jeffries seattle genetics sas jobs genetics jobs seattle wa seattle genetics kadcyla seattle genetics sage kelly seattle genetics 10k seattle genetics logo seattle genetics linkedin seattle genetics location seattle genetics lawsuit seattle genetics latest news seattle genetics liv1 seattle genetics leadership seattle genetics linker seattle genetics lab seattle genetics lymphoma seattle genetics market cap seattle genetics management seattle genetics mba internship seattle genetics mission seattle genetics multiple myeloma seattle genetics message board seattle genetics medical director seattle genetics media contact seattle genetics medical education grants seattle genetics morningstar seattle genetics number of employees seattle genetics nasdaq seattle genetics net worth seattle genetics nhl seattle genetics new drug seattle genetics natasha hernday seattle genetics stock news seattle genetics phone number seattle genetics inc nasdaq seattle genetics office seattle genetics oncology seattle genetics oncology pipeline seattle genetics outlook seattle genetics ocular toxicity seattle genetics opdivo seattle genetics orphan drug seattle genetics board of directors seattle genetics career opportunities seattle genetics press release seattle genetics products seattle genetics pbd seattle genetics presentation seattle genetics patents seattle genetics price seattle genetics pharmacy fellowship seattle genetics peter senter seattle genetics publications seattle genetics quote seattle genetics revenue seattle genetics reviews seattle genetics research associate salary seattle genetics recruiter seattle genetics roche seattle genetics reuters seattle genetics rumors https://www.youtube.com/watch?v=Iq_kyQL-Jd4&t
Views: 111 Biotech Stocks 1202
A Tipping Point For Cancer Treatment - Healthcare Summit (2014) | Forbes
 
40:12
New approaches in immune treatments and genetic technology mean that we’re making progress in ways that were previously unimaginable. Is vanquishing cancer possible? Subscribe to FORBES: https://www.youtube.com/user/Forbes?sub_confirmation=1 Stay Connected Forbes on Facebook: http://fb.com/forbes Forbes Video on Twitter: http://www.twitter.com/forbesvideo Forbes Video on Instagram: http://instagram.com/forbesvideo More From Forbes: http://forbes.com Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.
Views: 858 Forbes
V4P8: Cost Effectiveness of Antibody Drug Conjugate Technology
 
01:31
In Part 8 of our Interview with the Innovators series with Tom Reynolds, Chief Medical Officer of Seattle Genetics, focuses on the cost effectiveness and impact in the community.
Views: 119 GreenHillHC
Clinical Trial: Phase I CD-352 Antibody, Damian Green MD, Fred Hutchinson Cancer Research Center
 
05:01
A Phase I clinical trial for multiple myeloma patients who have had two lines of treatment including an immunomodulator and proteasome inhibitor. This study is in conjunction with Seattle Genetics
Views: 125 Myeloma Crowd TV
Improving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin Lymphom
 
40:01
Source: https://www.spreaker.com/user/7078249/joseph-connors-interview In this episode of The Onco'Zine Brief, Peter Hofland, Ph.D and Sonia Portillo talk with Dr. Joseph M. Connors, MD., FRCPC, Clinical Professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency. Dr. Connors is also the lead investigator of the ECHELON-1 clinical trial, a trial focusing on a new treatment option for Hodgekin Lymphoma. In this interview Hofland and Portillo talks with Dr. Connor about some of the latest results from the ECHELON-1 clinical trial, which tests an antibody-drug conjugate or ADC called brentuximab vedotin (ADCETRIS; being developed by Seattle Genetics and Takeda), as a frontline treatment option for patients with advanced classical Hodgkin Lymphoma. They also talk with Dr. Connors about how the ECHELON-1 study was conducted, and why it is important for this patient group, and for cancer research as a whole.
New US breast cancer drug
 
01:35
Subscribe to our channel http://bit.ly/AJSubscribe Subscribe to our channel http://bit.ly/AJSubscribe Touted as a major victory in the battle against breast cancer, researchers in the United States have announced a new class of chemotherapy drug. Scientists describe it as an "armed antibody", TDM1 is a "magic bullet" treatment, killing cancer cells without destroying the patients' quality of life. Al Jazeera's Anand Naidoo reports from Washington. At Al Jazeera English, we focus on people and events that affect people's lives. We bring topics to light that often go under-reported, listening to all sides of the story and giving a 'voice to the voiceless.' Reaching more than 270 million households in over 140 countries across the globe, our viewers trust Al Jazeera English to keep them informed, inspired, and entertained. Our impartial, fact-based reporting wins worldwide praise and respect. It is our unique brand of journalism that the world has come to rely on. We are reshaping global media and constantly working to strengthen our reputation as one of the world's most respected news and current affairs channels. Social Media links: Facebook: https://www.facebook.com/aljazeera Instagram: https://instagram.com/aljazeera/?ref=... Twitter: https://twitter.com/ajenglish Website: http://www.aljazeera.com/ google+: https://plus.google.com/+aljazeera/posts
Views: 1634 Al Jazeera English
Dr. Fanale Discusses Antibody-Drug Conjugates
 
01:48
Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of antibody-drug conjugates. For more information and resources about targeted therapies in cancer: http://targetedhc.com/
Views: 112 Targeted Oncology
V4 P4: Advantages of Antibody Drug Conjugates
 
01:55
Tom Reynolds, Chief Medical officer of Seattle Genetics, describes the advantages of antibody drug conjugates in this next segment of our Interview with the Innovators.
Views: 232 GreenHillHC
Dr. Zelenetz Discusses Brentuximab Vedotin
 
00:42
Andrew D. Zelenetz, MD, Chief, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Associate Professor of Medicine, Weill Cornell Medical College, believes that brentuximab vedotin (Adcetris), an antidrug conjugate, represents a very exciting treatment for patients. The FDA approved brentuximab vedotin to treat two types of lymphoma. The first indication came for refractory anaplastic large cell lymphoma and the second for Hodgkin lymphoma (HL) after the failure of either autologous stem cell transplant (ASCT) or 2 or more multi-agent chemotherapy regimens. Investigators are actively developing brentuximab vedotin to find new indications earlier in the treatment course. Zelenetz notes that if a benefit exists in early-stage HL then ASCT could be avoided in the relapsed or refractory setting.
Views: 333 OncLiveTV
Global Antibody Drug Conjugates Market 2016-2020
 
00:57
Link to Report: http://bit.ly/1UBz0VT Technavio’s market research analysts have predicted the antibody-drug conjugates (ADCs) market to grow stupendously at a tremendous CAGR of more than 41% during the forecast period. Several products in the late-pipeline stage of clinical trials are expected to be launched over the predicted period which is expected to drive the growth prospects of this market. For instance, products like glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals are to be launched in the next five years. Moreover, some molecules are in Phase I/II, preclinical, and discovery stages. Altogether, there are several ADCs in the pipeline and their approval in the forecast period is expected to aid in the growth of this market.
Views: 76 Technavio
New Lymphoma Drug SGN-35 - The Nebraska Medical Center
 
04:32
"This is really a breakthrough in that we finally have something to treat these really difficult to treat patients." The FDA approved SGN-35 as a treatment for Hodgkin's Lymphoma in August 2011. It is the first FDA-approved Hodgkin's treatment since 1977. The drug is also used to treat other rare types of lymphoma such as t-cell non-Hodgkin's Lymphoma. The drug is mono-clonal antibody which attacks a protein on the surface of a lymphoma cell. It seeks out the cancer cell directly and spares the normal healthy cells. It is given through the vein once every three weeks. In some cases, SGN-35 can be used to get a patient ready to undergo a stem cell transplant. The Nebraska Medical Center and its education and research partner, the University of Nebraska Medical Center have been international leaders in lymphoma and leukemia treatment and research for decades, in many cases pioneering treatments used around the world. As one of the medical centers involved in the clinical trials of SGN-35, the medical center's team has experience with this new treatment. For more information about the hematology/oncology program at The Nebraska Medical Center, visit http://www.nebraskamed.com/cancer or call 1-800-922-0000.
Views: 2018 Nebraska Medicine
IMG 7804
 
00:56
Adcetris Seattle Genetics - MOA model
Views: 72 Hanna Lee
Antibody-drug Conjugates - Where are we Going?
 
07:29
Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to be clinically evaluated in ongoing clinical research programs. While some of the trial results have indeed been impressive, some of the results have been mixed. At a time when some may worry about a high rate of attrition, researchers have correctly pointed out that a high rate of attrition in phase I and II means that only the best trial drugs advance to phase III trials and beyond. In reviewing the cause of failure of antibody-drug conjugates in clinical trials, researchers are looking at a great number of reasons, including the possibility of linker instability as one possible aspect causing systemic toxicity. But they are also asking if failure may be caused by safety concerns with maximum tolerable dose and low therapeutic index. Why does preclinical data not translate to clinical efficacy in human? Are these problems caused by an insufficient understanding of antibody-drug conjugate metabolism in vivo? In October 2015, during CPhI World Wide in Madrid, Spain we asked experts from Piramal Pharma Solutions, Carbogen Amcis and Catalent about challenges in the manufacturing of ADCs and how they see the market for ADCs evolve. © 2016 Developed and Produced by InPress Media Group, LLC for ADC Review / Journal of Antibody-drug Conjugates
Seattle Genetics Time Lapse video
 
02:31
Perlow Productions provided HD videography and video editing for this time lapse marketing video production. Learn more about Perlow Productions at www.perlowproductions.com .
Views: 77 PerlowProductions
T-Cell Lymphoma Clinical Trials
 
01:47
Our mission is to improve the cure rate of patients with PTCL and reduce treatment-related toxicity by developing novel targeted therapy using rationally designed small molecules, antibodies and combination regimens of biologic agents. For referrals, please contact ayounes@mdanderson.org or Amanda Copeland at ARCopeland@mdanderson.org.